• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600866.SS
Share

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong Stocks

CN¥ 4.34Last Updated 09.10.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.04B

CN¥ 4.34
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1964 and headquartered in Zhaoqing, China, Star Lake Bioscience Co., Inc. specializes in the production and global distribution of pharmaceutical ingredients, as well as food and animal feed additives. Its extensive product catalog includes guanosine, which serves as a crucial intermediate for both food and pharmaceutical applications. The company also manufactures L-proline, a vital intermediate for synthesizing captopril and enalapril, and a raw material used in amino acid transfusions. Another key offering is Adefovir dipivoxil tablets, formulated to combat Hepatitis B by inhibiting HBV DNA polymerase activity and disrupting the virus's DNA. Additionally, L-threonine is provided for its application in animal feed premixes, particularly for pigs and poultry. Star Lake Bioscience further supplies disodium 5'-ribonucleotide, utilized in the treatment of chronic hepatitis, muscular atrophy, and certain eye conditions. Similarly, disodium 5-inosinate addresses issues like leukopenia, thrombocytopenia, and both acute and chronic hepatitis. Inosine is another significant product, prescribed for various ailments including chronic hepatitis, heart disease, low white blood cell or platelet counts, and central choroidoretinitis. Furthermore, disodium 5'-guanylate finds application in food preservation, such as for canned meats, ham, and other salted meat products. The company's broad portfolio also features compounds such as ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, and L-lysine, among others. These diverse offerings are marketed under the proprietary brands Star Lake and Yue Bao.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 600866.SS is 5.28 and suggests 20% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

10.10.2026 04:58

Palantir shares hit a new high: Barclays followed Goldman in recommending a buy

10.10.2026 04:25

Apple has cut orders for parts for the new iPhones, according to media reports. Was demand lower than expected?

10.10.2026 03:01

An analyst sees Starlink's transition into a cell phone carrier as a problem for Apple and Samsung

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026